Experimental nanoparticle drug enters human testing for aggressive leukemia
NCT ID NCT04716452
Summary
This is an early-stage study to test the safety of a new drug called Ceramide NanoLiposome (CNL) in adults with acute myeloid leukemia (AML) that has returned or not responded to previous treatments. The main goal is to find a safe dose for future studies. Participants receive the drug by IV infusion twice a week and are closely monitored for side effects and how their disease responds.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA, REFRACTORY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Virginia Cancer Center
RECRUITINGCharlottesville, Virginia, 22903, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.